| 4.08 -2.28 (-35.85%) | 07-10 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 10.7 | 1-year : | 15.38 |
| Resists | First : | 9.16 | Second : | 13.17 |
| Pivot price | 3.59 |
|||
| Supports | First : | 2.68 | Second : | 2.23 |
| MAs | MA(5) : | 3.95 |
MA(20) : | 3.77 |
| MA(100) : | 4.44 |
MA(250) : | 10.08 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 24.1 |
D(3) : | 23 |
| RSI | RSI(14): 50.3 |
|||
| 52-week | High : | 28.5 | Low : | 2.5 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ VRAX ] has closed below upper band by 36.0%. Bollinger Bands are 40.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.97 - 4.99 | 4.99 - 5.02 |
| Low: | 3.96 - 3.98 | 3.98 - 4 |
| Close: | 4.04 - 4.08 | 4.08 - 4.12 |
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intended to support an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.
Fri, 10 Jul 2026
Virax Biolabs (Nasdaq: VRAX) secures $3.3M and issues new equity warrants - Stock Titan
Fri, 10 Jul 2026
$3.3M cash in, new Virax Biolabs warrants out at $6 a share - Stock Titan
Fri, 10 Jul 2026
Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds - PR Newswire
Fri, 10 Jul 2026
Morning Market Movers: GMM, JLHL, VRAX, FRMI See Big Swings - RTTNews
Thu, 09 Jul 2026
Virax Biolabs locks in $3.3M from option exercise deal - Stock Titan
Thu, 09 Jul 2026
Virax Biolabs Jumps on Fosun Diagnostics Supply Agreement - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 122850 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 16 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.56e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -160 % |
| Return on Assets (ttm) | 788.3 % |
| Return on Equity (ttm) | -48.5 % |
| Qtrly Rev. Growth | 2990 % |
| Gross Profit (p.s.) | -54.44 |
| Sales Per Share | -67.6 |
| EBITDA (p.s.) | -36540.3 |
| Qtrly Earnings Growth | -30.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.07 |
| Price to Cash Flow | 6.24 |
| Dividend | 0 |
| Forward Dividend | 40980 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|